• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自身中和抗体反应的特异性。

Specificity of the autologous neutralizing antibody response.

机构信息

AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.

出版信息

Curr Opin HIV AIDS. 2009 Sep;4(5):358-63. doi: 10.1097/COH.0b013e32832ea7e8.

DOI:10.1097/COH.0b013e32832ea7e8
PMID:20048698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3004050/
Abstract

PURPOSE OF REVIEW

It has long been known that autologous neutralizing antibodies (AnAbs) exert pressure on the envelope of HIV, resulting in neutralization escape. However, recently, progress has been made in uncovering the precise targets of these potent early antibodies.

RECENT FINDINGS

AnAbs primarily target variable regions of the HIV-1 envelope, explaining the strain-specificity of these antibodies. Despite high neutralizing potential and cross-reactivity, anti-V3 antibodies do not contribute to autologous neutralization. The V1V2 is commonly immunogenic in early HIV-1 and simian human immunodeficiency virus infections, though the nature of these epitopes remains to be determined. In subtype C viruses, the C3 region is a neutralization target, possibly as a result of its more exposed and amphipathic structure. Autologous neutralization appears to be mediated by very few AnAb specificities that develop sequentially suggesting the possibility of immunological hierarchies for both binding and neutralizing antibodies. The role of AnAbs in preventing superinfection and in restricting virus replication is reexamined in the context of recent data.

SUMMARY

New studies have greatly contributed toward our understanding of the specificities mediating autologous neutralization and highlighted potential vulnerabilities on transmitted viruses. However, the contribution of AnAbs to the development of neutralization breadth remains to be characterized.

摘要

目的综述

长期以来,人们一直知道,自体中和抗体(AnAbs)对 HIV 的包膜施加压力,导致中和逃逸。然而,最近,人们在揭示这些强效早期抗体的确切靶标方面取得了进展。

最近的发现

AnAbs 主要针对 HIV-1 包膜的可变区,解释了这些抗体的株特异性。尽管具有高中和潜力和交叉反应性,但抗 V3 抗体不能促进自体中和。V1V2 在早期 HIV-1 和猴免疫缺陷病毒感染中通常具有免疫原性,尽管这些表位的性质仍有待确定。在 C 型病毒中,C3 区是中和的靶标,可能是由于其更暴露和两亲性结构。自体中和似乎是由少数顺序发展的 AnAb 特异性介导的,这表明结合抗体和中和抗体都有可能存在免疫等级。新的研究极大地促进了我们对介导自体中和的特异性的理解,并强调了传播病毒上的潜在弱点。然而,自体中和抗体对中和广度的发展的贡献仍有待表征。

相似文献

1
Specificity of the autologous neutralizing antibody response.自身中和抗体反应的特异性。
Curr Opin HIV AIDS. 2009 Sep;4(5):358-63. doi: 10.1097/COH.0b013e32832ea7e8.
2
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.从一名感染HIV-1 C亚型的精英中和者体内获得的构象表位特异性广泛中和性血浆抗体通过V1环区的突变介导自体病毒逃逸。
J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.
3
Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.HIV-1 CRF01_AE 急性感染中抗体反应的演变:原发型包膜 V1V2 影响自体中和抗体的出现时间和幅度。
J Virol. 2023 Feb 28;97(2):e0163522. doi: 10.1128/jvi.01635-22. Epub 2023 Feb 7.
4
HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.非人灵长类动物免疫接种引发的HIV-1交叉反应性原发性病毒中和抗体反应
J Virol. 2017 Oct 13;91(21). doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.
5
Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.V3/C3结构域突变与HIV-1 C亚型原代包膜对自身广泛中和血浆抗体的敏感性增强之间的关联。
Retrovirology. 2016 Jun 15;13(1):41. doi: 10.1186/s12977-016-0273-x.
6
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.有限的中和抗体特异性驱动HIV-1 C亚型早期感染中的中和逃逸。
PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.
7
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.BG505 艾滋病毒 1 型包膜中的 C3/465 聚糖孔簇是主要的中和靶点,可预防粘膜性 SHIV 感染。
PLoS Pathog. 2021 Feb 8;17(2):e1009257. doi: 10.1371/journal.ppat.1009257. eCollection 2021 Feb.
8
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.在1型人类免疫缺陷病毒C亚型感染中,C3-V4区域是自体中和抗体的主要靶标。
J Virol. 2008 Feb;82(4):1860-9. doi: 10.1128/JVI.02187-07. Epub 2007 Dec 5.
9
Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.HIV 包膜关键残基的正选择可区分广谱和株特异性血浆中和抗体。
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.01685-18. Print 2019 Mar 15.
10
Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.通过对包膜免疫原进行策略性选择实现针对2级HIV-1病毒的强效自体中和抗体反应。
J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

引用本文的文献

1
Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.中和威胁:利用抗HIV-1的广谱中和抗体进行治疗和预防。
Microb Cell. 2024 Jul 3;11:207-220. doi: 10.15698/mic2024.07.826. eCollection 2024.
2
Assessing immunogenicity barriers of the HIV-1 envelope trimer.评估HIV-1包膜三聚体的免疫原性障碍。
NPJ Vaccines. 2023 Sep 30;8(1):148. doi: 10.1038/s41541-023-00746-3.
3
Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption.自体中和抗体随着早期抗逆转录病毒治疗而增加,并影响治疗中断后 HIV 的反弹。
Sci Transl Med. 2023 May 10;15(695):eabq4490. doi: 10.1126/scitranslmed.abq4490.
4
Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.HIV-1 CRF01_AE 急性感染中抗体反应的演变:原发型包膜 V1V2 影响自体中和抗体的出现时间和幅度。
J Virol. 2023 Feb 28;97(2):e0163522. doi: 10.1128/jvi.01635-22. Epub 2023 Feb 7.
5
Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression.人类免疫缺陷病毒1型包膜糖蛋白在艾滋病发病机制及临床进展中的作用
Biomedicines. 2022 Sep 2;10(9):2172. doi: 10.3390/biomedicines10092172.
6
HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies.HIV 合并感染为设计引发广泛中和抗体的疫苗鸡尾酒提供了思路。
J Virol. 2022 Jul 27;96(14):e0032422. doi: 10.1128/jvi.00324-22. Epub 2022 Jun 27.
7
The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.HIV-1包膜糖蛋白的特性与病毒发病机制相关。
Front Microbiol. 2022 Mar 24;13:763039. doi: 10.3389/fmicb.2022.763039. eCollection 2022.
8
Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization.HIV-1 V3环冠的不同构象可成为广泛中和作用的靶点。
Nat Commun. 2021 Nov 18;12(1):6705. doi: 10.1038/s41467-021-27075-0.
9
Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.第一代 gp41 稳定的 HIV-1 包膜三聚体和纳米颗粒诱导的中和抗体。
mBio. 2021 Jun 29;12(3):e0042921. doi: 10.1128/mBio.00429-21. Epub 2021 Jun 22.
10
Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity.一名具有广泛中和活性的HIV-1 B'亚型感染血浆供体中的病毒进化与中和敏感性
Vaccines (Basel). 2021 Mar 25;9(4):311. doi: 10.3390/vaccines9040311.

本文引用的文献

1
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.有限的中和抗体特异性驱动HIV-1 C亚型早期感染中的中和逃逸。
PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.
2
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.在急性感染和接种疫苗后,具有广泛反应性但中和效力较低的高滴度HIV-1 V3特异性抗体。
Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.
3
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.从HIV感染个体的记忆B细胞中分离出的中和抗体具有广泛的多样性。
Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.
4
Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.HIV-1感染中记忆B细胞与循环抗Env抗体反应的不一致性
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. doi: 10.1073/pnas.0813392106. Epub 2009 Feb 18.
5
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.来自印度的新传播C亚型HIV-1 Env克隆的单系谱系上高度复杂的中和决定簇。
Virology. 2009 Mar 15;385(2):505-20. doi: 10.1016/j.virol.2008.12.032. Epub 2009 Jan 23.
6
A method for identification of HIV gp140 binding memory B cells in human blood.一种鉴定人血液中HIV gp140结合记忆B细胞的方法。
J Immunol Methods. 2009 Apr 15;343(2):65-7. doi: 10.1016/j.jim.2008.11.012. Epub 2008 Dec 25.
7
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.2型人类免疫缺陷病毒(HIV-2)/HIV-1包膜嵌合体可检测出人血浆中高滴度的具有广泛反应性的HIV-1 V3特异性抗体。
J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.
8
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.对来自1型人类免疫缺陷病毒感染个体的多克隆血清中的中和特异性进行分析。
J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.
9
Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.初治的人类免疫缺陷病毒控制者中病毒持续逃逸及自体中和抗体的选择作用
J Virol. 2009 Jan;83(2):662-72. doi: 10.1128/JVI.01328-08. Epub 2008 Nov 5.
10
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.1型人类免疫缺陷病毒感染期间与交叉反应性中和抗体产生相关的因素。
J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5.